Tablet drug for advanced EGFR-mutated lung cancer after prior therapy
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 study tests a new oral (tablet) cancer medicine called BPI-361175 in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. It aims to see how the drug should be dosed and whether it can help shrink or control tumors when earlier standard treatments no longer worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old.
- Your overall condition is good enough for treatment (ECOG 0–1).
- You have inoperable or advanced NSCLC that has an EGFR mutation, and standard treatment didn’t work or wasn’t tolerated.
- If you’re joining the later part of the study, your tumor must be confirmed to have the EGFR C797S mutation and imaging must show your cancer is growing.
- You must have at least one measurable tumor spot for the later study part.
- Your blood counts, liver, and kidneys must meet lab minimums, and past side effects from earlier treatment must mostly be back to mild levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
Hear when a new Non-small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.